Progress DNDI-6148, an oxaborole compound, through clinical development for the treatment of leishmaniasis
current phase of drug development
updated 15 Feb 2023
DNDi’s screening of Anacor’s library of drug compounds from the oxaborole class, followed by focused medicinal chemistry efforts, led to the discovery of a number of analogues showing efficacy in animal models of Chagas disease, leishmaniasis, and sleeping sickness.
One of these compounds, acoziborole, has completed a Phase II/III trials for sleeping sickness. An analogue compound, DNDI-6148, emerged as a promising lead candidate and was shown to be effective against Leishmania strains in various in vitro and in vivo studies. In late 2018, the decision was made to progress DNDI-6148 to a first-in-human Phase I single ascending dose study in healthy volunteers.
News & resources
- 28 October 2021 - DNDI-6148: A novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis, Journal of Medicinal Chemistry
- 29 June 2021 - Identification of resistance determinants for a promising antileishmanial oxaborole series, Microorganisms
Get our latest news, personal stories, research articles, and job opportunities.